ILX002 is Illexcor Therapeutics' lead drug candidate designed as a first-in-class oral medication that directly combats the causes of sickle cell disease. It operates by binding to hemoglobin S, effectively preventing the polymerization that leads to the sickling of red blood cells, even under low oxygen conditions.

• ·Targets hemoglobin S to prevent polymerization
• ·Inhibits sickling of red blood cells
• ·Proven efficacy in preclinical studies